Objective: To assess the therapeutic effect of tDCS on cognitive function in patients with Parkinson's disease.
Methods: From the start of the library's construction until June 24, 2024, we searched the following databases for literature: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, China Science and Technology Journal Database (VIP), and China Biomedical Literature Database (CBM). We also looked through the references in the articles. The improvement of overall cognition in patients with Parkinson's disease with tDCS was the primary outcome indicator. The improvement of executive function, memory, attention, language, quality of life, and depression with tDCS were the secondary outcome indicators. Two researchers extracted data independently, with a third researcher mediating in the event of a dispute. The Cochrane risk of bias tool was used to evaluate the quality of the included literature.
Results: A total of 23 articles encompassing 874 subjects were included. tDCS has shown significant efficacy on overall cognition (SMD = 0.73, 95% CI = 0.57 to 0.89, I = 0%, < 0.00001), particularly in the areas of executive function (SMD = -0.32, 95% CI = -0.56 to -0.07, I = 0%, = 0.01) and language function (SMD = 0.5, 95% CI = 0.2 to 0.8, I = 0%, P = 0.001). Furthermore, the clinical efficacy of tDCS was enhanced with a stimulation intensity of 2 mA (SMD = 0.76, 95% CI = 0.58 to 0.93, I = 7%, < 0.00001), a stimulation duration of ≥25 min (SMD = 0.70, 95% CI = 0.49 to 0.91, I = 6%, < 0.00001), and a minimum of 10 stimulation sessions (SMD = 0.74, 95% CI = 0.56 to 0.92, I = 0%, < 0.00001). Furthermore, tDCS has shown efficacy in alleviating depressive mood (SMD = -0.46, 95% CI = -0.79 to -0.13, I = 0%, = 0.006).
Conclusion: tDCS demonstrated substantial efficacy in enhancing overall cognition in patients with PD. The efficacy of tDCS was obvious in executive function, language, and depressive mood. Nonetheless, a substantial quantity of rigorous clinical trials on tDCS for cognitive function in patients with PD remains necessary in the future.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880240 | PMC |
| http://dx.doi.org/10.3389/fnagi.2025.1495492 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction of dementia using CT imaging in stroke (PRODUCTS).
Eur Stroke J
March 2025
Institute of Cardiovascular and Metabolic Sciences, University of Glasgow, Glasgow, UK.
Introduction: A better understanding of who will develop dementia can inform patient care. Although MRI offers prognostic insights, access is limited globally, whereas CT-imaging is readily available in acute stroke. We explored the prognostic utility of acute CT-imaging for predicting dementia.
View Article and Find Full Text PDFThe impact of a virtual wound on pain sensitivity: insights into the affective dimension of pain.
Front Pain Res (Lausanne)
February 2025
Centre for Human Drug Research, Leiden, Netherlands.
Background: The perception of pain is difficult to assess due to the complex combination of various components related to nociception, experience, and cognition. There are currently no biomarkers to assess the affective component of pain in healthy volunteers. Using Virtual Reality (VR), it may be possible to assess changes in pain perception when adding an affective component to painful stimulation.
View Article and Find Full Text PDFEyebrow movements as signals of communicative problems in human face-to-face interaction.
R Soc Open Sci
March 2025
Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands.
Repair is a core building block of human communication, allowing us to address problems of understanding in conversation. Past research has uncovered the basic mechanisms by which interactants signal and solve such problems. However, the focus has been on verbal interaction, neglecting the fact that human communication is inherently multimodal.
View Article and Find Full Text PDFBackground And Aims: Alzheimer's disease (AD) is a widespread neurodegenerative condition that has a growing impact on a global scale. This study aims to examine the relationship between cerebral blood flow (CBF) and the synaptic biomarker growth-associated protein 43 (GAP-43) through the utilization of arterial spin labeling (ASL). The research identified noteworthy correlations between cerebrospinal fluid (CSF) GAP-43 levels, CBF, and cognitive composite scores, especially among participants with mild cognitive impairment (MCI) who possess the APOE-ε4 gene.
View Article and Find Full Text PDFCould immunotherapy and regulatory T cells be used therapeutically to slow the progression of Alzheimer's disease?
Brain Commun
February 2025
Neuroscience, Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter EX2 4TH, UK.
Alzheimer's disease and other cognitive impairments are a growing problem in the healthcare world with the ageing population. There are currently no effective treatments available; however, it has been suggested that targeting neuroinflammation may be a successful approach in slowing the progression of neurodegeneration. Reducing the destructive hyperinflammatory pathology to maintain homeostasis in neural tissue is a promising option to consider.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!